Laboratory Medicine banner
     
HomeFaculty › Petrie M. Rainey

Petrie M. Rainey, M.D., PhD

Photo of Dr. Rainey

Professor, Laboratory Medicine
School of Medicine
University of Washington

  • Department of Laboratory Medicine
  • University of Washington
  • Box 357110
  • Seattle, WA 98195-7110
  •  
  • Tel: (206)-598-6131
  • Fax: (206)-598-6189
  • Email: pmrainey@u.washington.edu

Qualifications

  • BS, 1968, University of North Carolina
  • PhD, 1973, University of California, Berkeley
  • MD, 1980, University of North Carolina
  • Fellowships: University of California, San Francisco; University of Regensburg, Germany

Research Interests

I have a variety of research interests related to therapeutic drugs, including development of analytical methods, investigations of pharmacokinetics, molecular and cellular investigations of mechanisms of action and resistance, and clinical studies. These have provided an assortment of projects for Laboratory Medicine residents and fellows, as well as undergraduate, graduate and medical students. Current research falls in three basic areas:

  • the pharmacology of drugs used in the treatment of HIV infection;
  • various investigations related to Laboratory Medicine; and
  • Leishmaniasis and its treatment.

AIDS pharmacology

Pharmacokinetics and pharmacodynamics of drugs used to treat HIV infection and associated opportunistic infections. We are currently studying interactions between anti-HIV drugs (reverse transcriptase inhibitors and protease inhibitors) and drugs used to treat substance abuse (methadone, buprenorphine).

References:

  1. V. A. Gruber, P. M. Rainey, D. E. Moody, G. D. Morse, Q. Ma, S. Prathikanti, P. A. Pade, A. A. H. Alvanzo, and E. F. McCance-Katz. Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir. Clin Infect Dis 2012; 54: 414-423. [Medline abstract]

  2. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not Rifabutin, May Produce Opiate Withdrawal in Buprenorphine-Maintained Patients. Drug Alcohol Depend 2011; 118: 326-334. [Medline Abstract]

  3. McCance-Katz EF, Rainey PM, Moody DE. Effect of cocaine use on buprenorphine pharmacokinetics in humans. Am J Addict. 2010; 19:38-46. [Medline Abstract]

  4. Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am J Addict. 2010; 19:17-29. [Medline Abstract]

Laboratory Medicine

We carry out various investigations, both analytical and clinical, related to clinical chemistry, therapeutic drug monitoring and toxicology.

References:

  1. Strathmann FG, Ka MM, Rainey PM, Baird GS. Use of the BD Vacutainer Rapid Serum Tube reduces false-positive results for selected Beckman Coulter Unicel DxI Immunoassays. Am J Clin Pathol 2011; 136:325-329. [Medline Abstract]

  2. Rainey PM. Laboratory Principles. In: L.S. Nelson, N.A. Lewin, M.A. Howland et al., Eds. Goldfrank's Toxicologic Emergencies, 9th Ed. McGraw-Hill, New York, 2011: 70-89.

  3. Platteborze PL, Rainey PM, Baird GS. Ketoacidosis with Unexpected Serum Isopropyl Alcohol. Clin Chem 2011; 57:1361-1365. [Article]

  4. Sobhani K, Garrett DA, Liu DP, Rainey PM. A rapid and simple HPLC assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant patients. Am J Clin Pathol 2010; 133:454-457. [Medline Abstract]

  5. Baird GS, Rainey PM, Wener M, Chandler W. Reducing Routine Ionized Calcium Measurement. Clin Chem 2009; 55:533-540. [Medline Abstract]

leishmaniasisLeishmaniasis

The leishmaniases are a family of diseases caused by the parasitic protozoan Leishmania . We have been able to reproduce the entire life cycle in vitro and have used this system to study the regulation of gene expression during the transformations between amastigote and promastigote life stages. We are currently investigating the composition, mechanism of action and pharmacokinetics of the antileishmanial drugs, sodium stibogluconate and meglumine antimoniate.

We carry out various investigations, both analytical and clinical, related to clinical chemistry, therapeutic drug monitoring and toxicology.

References:

  1. Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate. J Infect Dis 2007; 195:602-608. [Medline Abstract]

  2. Roberts WL, McMurray WJ, Rainey PM. Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob Agents Chemother 1998 May;42(5):1076-1082. (See model on right of 'Proposed Structure for Meglumine Antimonate (n=2)'). [Medline Abstract]

  3. Roberts WL, Berman JD, Rainey PM. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations. Antimicrob Agents Chemother 1995 Jun;39(6):1234-1239. [Medline Abstract]

  4. Campbell SM, Rainey PM. Leishmania pifanoi: kinetics of messenger RNA expression during amastigote to promastigote transformation in vitro. Exp Parasitol 1993 Aug;77(1):1-12. [Medline Abstract]

Professional Activities

Dr. Rainey is the Director of the Chemistry Division of the Department of Laboratory Medicine and also serves as the Director of the Clinical Pathology Track of the Pathology Residency Training Program. He was the founding Chair of the Point of Care Testing Division of the American Association for Clinical Chemistry ( AACC ). He also helped to found the International Association for Therapeutic Drug Monitoring and Clinical Toxicology ( IATDMCT ) and served as the first Director of Education. Dr. Rainey is a past President of the Academy of Clinical Laboratory Physicians and Scientists ( ACLPS ) and also is active in the American College of Medical Toxicology ( ACMT ). He is on the editorial board of the journal Clinica Chimica Acta.

Additional information is available at Husky SciVal Experts.

Last updated: 11/15/12